Archive \ Volume.12 2021 Issue 1

A review on updates in management and Treatment of Psoriasis

Ibtihal M. Alhammad , Amal M. Aseri , Sultan A. M. Alqahtani , Malak F. Alshaebi , Shahad A. Alqahtani , Rawan A. Alzahrani , Ahmed A. Alhaji , Mohammed K. Alamoudi , Ammar Y. Bafarat , Ammar Y. Jad , Alaa E. Nuqali

Introduction: Introduction: Psoriasis is a rather common inflammatory skin disease that is characterized by the appearance of red scaly plaques and may affect any part of the body. There are certain factors that make psoriasis a challenge for physicians, these include: high prevalence, disability, chronicity, disfiguration, and associated comorbidities. The approach to the management of Psoriatic patients should also take into account the dermatological clinical features. This review would discuss and focus on recent updates in the management of Psoriatic patients and its common related issues as well as the clinical picture of psoriasis in order to understand and inform medical practitioners and develop their knowledge of the etiology of the condition, immune and environmental factors, has led to the development of precision-targeted therapies that alleviate patient morbidity. Methodology: PubMed database was searched and screened for relevant observational studies, systematic reviews, randomized controlled trials, meta-journal articles, and journal articles containing the term used in the mesh “Psoriasis”, “Management” “Treatment trials” within the title or abstract. Conclusion: The physician should adhere to updated evidence-based guidelines in the management of psoriatic patients. New biologic modalities and alternative nature-based treatments for psoriasis should be studied. Pharmacodynamics profiles, administration modality, and dosing regimens for the currently available IL-17 and IL-23 inhibitors must be re-examined to improve the overall continuity of care of psoriasis patients.

How to cite:
Alhammad IM, Aseri AM, Alqahtani SAM, Alshaebi MF, Alqahtani SA, Alzahrani RA, et al. A review on updates in management and Treatment of Psoriasis. Arch. Pharm. Pract. 2021;12(1):74-8.
Alhammad, I. M., Aseri, A. M., Alqahtani, S. A. M., Alshaebi, M. F., Alqahtani, S. A., Alzahrani, R. A., Alhaji, A. A., Alamoudi, M. K., Bafarat, A. Y., Jad, A. Y., & et al (2021). A review on updates in management and Treatment of Psoriasis. Archives Of Pharmacy Practice, 12(1),74-78.

Download Citation
  1. Boehncke, W. H., & Schön, M. P. Disease burden and epidemiology. Lancet. 2015;386, 983-994.

  2. Rendon, A., & Schäkel, K. Psoriasis pathogenesis and treatment. International journal of molecular sciences.2019;20(6), 1475. doi: 10.3390/ijms20061475. Review. PMID: 30909615.

  3. Lim, D. S., Bewley, A., & Oon, H. H. Psychological Profile of patients with psoriasis. Ann Acad Med Singap. 2018;47(12), 516-522.

  4. Christophers, E. Psoriasis− epidemiology and clinical spectrum. Clinical and experimental dermatology. 2001; 26(4), 314-320.

  5. Pezzolo, E., Cazzaniga, S., Colombo, P., Chatenoud, L., & Naldi, L. Psoriasis Incidence and Lifetime Prevalence: Suggestion for a Higher Mortality Rate in Older Age-classes among Psoriatic Patients Compared to the General Population in Italy. Acta dermato-venereologica. 2019; 99(3), 400-403. doi: 10.2340/00015555-3130.

  6. Kimball, A. B., Wu, E. Q., Guérin, A., Andrew, P. Y., Tsaneva, M., Gupta, S. R., ... & Mulani, P. M. Risks of developing psychiatric disorders in pediatric patients with psoriasis. Journal of the American Academy of Dermatology. 2012; 67(4), 651-657.

  7. Di Lernia, V., & Goldust, M. An overview of the efficacy and safety of systemic treatments for psoriasis in the elderly. Expert Opinion on Biological Therapy. 2018; 18(8), 897-903. doi: 10.1080/14712598.2018.1504016. Epub 2018 Jul 26.

  8. Fernandez-Torres, R. M., Paradela, S., & Fonseca, E. Psoriasis in patients older than 65 years. A comparative study with younger adult psoriatic patients. The journal of nutrition, health & aging. 2012; 16(6), 586-591.

  9. Augustin, M., Glaeske, G., Radtke, M. A., Christophers, E., Reich, K., & Schäfer, I. Epidemiology and comorbidity of psoriasis in children. British Journal of Dermatology. 2012;162(3), 633-636.

  10. Becker, L., Tom, W. L., Eshagh, K., Benjamin, L. T., & Paller, A. S. Excess adiposity preceding pediatric psoriasis. JAMA dermatology. 2014; 150(5), 573-574.

  11. Paller, A. S., Mercy, K., Kwasny, M. J., Choon, S. E., Cordoro, K. M., Girolomoni, G., ... & Seyger, M. M. Association of pediatric psoriasis severity with excess and central adiposity: an international cross-sectional study. JAMA dermatology. 2013;149(2), 166-176.

  12. Icen, M., Crowson, C. S., McEvoy, M. T., Dann, F. J., Gabriel, S. E., & Kremers, H. M. Trends in incidence of adult-onset psoriasis over three decades: a population-based study. Journal of the American Academy of Dermatology. 2009; 60(3), 394-401.

  13. Tollefson, M. M., Crowson, C. S., McEvoy, M. T., & Kremers, H. M. Incidence of psoriasis in children: a population-based study. Journal of the American Academy of Dermatology. 2010; 62(6), 979-987.

  14. Capon, F. The genetic basis of psoriasis. International Journal of Molecular Sciences. 2017; 18(12), 2526.

  15. Gladman, D. D., Anhorn, K. A., Schachter, R. K., & Mervart, H. HLA antigens in psoriatic arthritis. The Journal of rheumatology, 1986; 13(3), 586-592.

  16. Hugh, J. M., & Weinberg, J. M. Update on the pathophysiology of psoriasis. Cutis. 2018; 102(5S), 6-12.

  17. Søyland, E., Heier, I., Rodríguez‐Gallego, C., Mollnes, T. E., Johansen, F. E., Holven, K. B., ... & Nenseter, M. S. Sun exposure induces rapid immunological changes in skin and peripheral blood in patients with psoriasis. British Journal of Dermatology. 2011; 164(2), 344-355. doi: 10.1111/j.1365-2133.2010.10149.x.

  18. Kim, W. B., Jerome, D., & Yeung, J. Diagnosis and management of psoriasis. Canadian Family Physician, 2017;63(4), 278-285.

  19. Zampetti, A., & Tiberi, S. Inverse psoriasis. Clinical Medicine. 2015;15(3), 311.

  20. Dupire, G., Droitcourt, C., Hughes, C., & Le Cleach, L. Antistreptococcal interventions for guttate and chronic plaque psoriasis. Cochrane Database of Systematic Reviews, 2019;(3), DOI: 10.1002/14651858.CD011571.pub2.

  21. Hoegler, K. M., John, A. M., Handler, M. Z., & Schwartz, R. A. Generalized pustular psoriasis: a review and update on treatment. Journal of the European Academy of Dermatology and Venereology. 2018; 32(10), 1645-1651.

  22. Engin, B., Aşkın, Ö., & Tüzün, Y. Palmoplantar psoriasis. Clinics in dermatology. 2017; 35(1), 19-27.

  23. Arellano, J., Yagnam, M., Vidal, M., & Corredoira, Y. Eritrodermia psoriática en un hombre joven: sospechar infección por VIH. Revista chilena de infectología. 2017; 34(6), 603-606.

  24. Valenzuela, F., Fernández, J., Sánchez, M., & Zamudio, A. Erythrodermic psoriasis and human immunodeficiency virus: association and therapeutic challenges. Anais brasileiros de dermatologia. 2018; 93(3), 438-440.

  25. Pasch, M. C. Nail psoriasis: a review of treatment options. Drugs. 2016; 76(6), 675-705.

  26. Alinaghi, F., Calov, M., Kristensen, L. E., Gladman, D. D., Coates, L. C., Jullien, D., ... & Egeberg, A. Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational and clinical studies. Journal of the American Academy of Dermatology. 2019; 80(1), 251-265.

  27. Cruz, N. F. S. D., Brandão, L. S., Cruz, S. F. S. D., Cruz, S. A. S. D., Pires, C. A. A., & Carneiro, F. R. O. Manifestações oculares observadas em pacientes com psoríase. Arquivos Brasileiros de Oftalmologia. 2018; 81(3), 219-225.

  28. Mrowietz, U., Kragballe, K., Reich, K., Spuls, P., Griffiths, C. E. M., Nast, A., ... & Yawalkar, N. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Archives of dermatological research. 2011; 303(1), 1-10.

  29. MacDonald, A., & Burden, A. D. Psoriasis: advances in pathophysiology and management. Postgraduate medical journal. 2007; 83(985), 690-697.

  30. Kim, H. J., & Lebwohl, M. G. Biologics and psoriasis: the beat goes on. Dermatologic clinics. 2019; 37(1), 29-36.

  31. Egeberg, A., Ottosen, M. B., Gniadecki, R., Broesby‐Olsen, S., Dam, T. N., Bryld, L. E., ... & Skov, L. Safety, efficacy and drug survival of biologics and biosimilars for moderate‐to‐severe plaque psoriasis. British Journal of Dermatology. 2018; 178(2), 509-519.

  32. Wang, T. S., & Tsai, T. F. Biologics switch in psoriasis. Immunotherapy. 2019; 11(6), 531-541.

  33. Loft, N. D., Vaengebjerg, S., Halling, A. S., Skov, L., & Egeberg, A. (2020). Adverse events with IL‐17 and IL‐23 inhibitors for psoriasis and psoriatic arthritis: a systematic review and meta‐analysis of phase III studies. Journal of the European Academy of Dermatology and Venereology, 34(6), 1151-1160.

  34. Kamata, M., & Tada, Y. Efficacy and Safety of Biologics for Psoriasis and Psoriatic Arthritis and Their Impact on Comorbidities: A Literature Review. International Journal of Molecular Sciences. 2020; 21(5), 1690. doi: 10.3390/ijms21051690. PMID: 32121574; PMCID: PMC7084606.

  35. Kazandjieva, J., Grozdev, I., Darlenski, R., & Tsankov, N. (Climatotherapy of psoriasis. Clinics in dermatology. 2008; 26(5), 477-485. doi:10.1016/j.clindermatol.2008.05.001.